BRPI0412262A - derivados de azepina como agentes farmacêuticos - Google Patents

derivados de azepina como agentes farmacêuticos

Info

Publication number
BRPI0412262A
BRPI0412262A BRPI0412262-3A BRPI0412262A BRPI0412262A BR PI0412262 A BRPI0412262 A BR PI0412262A BR PI0412262 A BRPI0412262 A BR PI0412262A BR PI0412262 A BRPI0412262 A BR PI0412262A
Authority
BR
Brazil
Prior art keywords
pharmaceutical agents
azepine derivatives
receptor activity
azepine
derivatives
Prior art date
Application number
BRPI0412262-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Richard Martin
Tie-Lin Wang
Brenton T Flatt
Xiao-Hui Gu
Original Assignee
X Ceptor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by X Ceptor Therapeutics Inc filed Critical X Ceptor Therapeutics Inc
Publication of BRPI0412262A publication Critical patent/BRPI0412262A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0412262-3A 2003-07-23 2004-07-23 derivados de azepina como agentes farmacêuticos BRPI0412262A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48985403P 2003-07-23 2003-07-23
PCT/US2004/023745 WO2005009387A2 (en) 2003-07-23 2004-07-23 Azepine derivatives as pharmaceutical agents

Publications (1)

Publication Number Publication Date
BRPI0412262A true BRPI0412262A (pt) 2006-09-19

Family

ID=34102943

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412262-3A BRPI0412262A (pt) 2003-07-23 2004-07-23 derivados de azepina como agentes farmacêuticos

Country Status (14)

Country Link
US (1) US8466143B2 (enExample)
EP (1) EP1648408A4 (enExample)
JP (1) JP4679517B2 (enExample)
KR (1) KR20060052867A (enExample)
CN (1) CN1852748A (enExample)
AU (1) AU2004259009A1 (enExample)
BR (1) BRPI0412262A (enExample)
CA (1) CA2532798C (enExample)
CR (1) CR8258A (enExample)
EC (1) ECSP066392A (enExample)
IL (1) IL173287A0 (enExample)
NO (1) NO20060871L (enExample)
RU (1) RU2006105646A (enExample)
WO (1) WO2005009387A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
WO2005040169A2 (en) 2003-09-17 2005-05-06 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds as serotonin receptor modulators
ES2321028T3 (es) 2005-03-14 2009-06-01 Glaxo Group Limited Derivados de tiazol condensados que tienen afinidad por el receptor h3 de histamina.
JP5420908B2 (ja) * 2005-12-15 2014-02-19 エグゼリクシス， インコーポレイテッド 医薬的薬剤としてのアゼピノインドール誘導体
US20080299118A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
US20080300235A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20090163474A1 (en) * 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) * 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
CA2742320A1 (en) 2008-10-31 2010-05-06 Medivation Technologies, Inc. Pyrido[4,3-b]indoles containing rigid moieties
AU2009308708B2 (en) * 2008-10-31 2015-11-19 Medivation Technologies, Inc. Azepino [4, 5-b] indoles and methods of use
CN101875627B (zh) * 2009-04-30 2014-01-15 凯惠科技发展(上海)有限公司 一种1-烷氧羰基-2h-异吲哚衍生物及其制备方法和中间体
SG10201706590VA (en) 2009-05-22 2017-09-28 Abbvie Inc Modulators of 5-ht receptors and methods of use thereof
WO2011103485A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103433A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
RU2567751C2 (ru) * 2010-05-21 2015-11-10 Эббви Инк. Трициклические производные пирролидина, полезные в качестве модуляторов 5-ht рецепторов
IN2013MN01699A (enExample) * 2011-02-18 2015-06-12 Medivation Technologies Inc
US20140303144A1 (en) 2011-02-18 2014-10-09 Medivation Technologies, Inc. Compounds and methods of treating hypertension
EP2887805A4 (en) * 2012-08-22 2016-08-17 Medivation Technologies Inc COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
KR20170117020A (ko) * 2014-11-21 2017-10-20 아카나 테라퓨틱스, 엘티디. 질병의 치료를 위한 융합된 비시클릭 화합물
RU2741387C2 (ru) 2014-12-22 2021-01-25 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
JP6843061B2 (ja) * 2015-03-26 2021-03-17 アカーナ・セラピューティクス・リミテッドＡｋａｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｔｄ． 疾患治療のための縮合二環化合物
WO2017143134A1 (en) * 2016-02-19 2017-08-24 Alios Biopharma, Inc. Fxr modulators and methods of their use
BR112018073460A2 (pt) * 2016-05-25 2019-07-09 Akarna Therapeutics Ltd terapias combinadas usando moduladores do receptor farnesoide x (fxr)
US20200325140A1 (en) * 2016-05-25 2020-10-15 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
CA3065313A1 (en) * 2017-06-02 2018-12-06 Akarna Therapeutics, Ltd. Fused bicyclic compounds
BR112020015199A2 (pt) 2018-01-26 2021-05-04 Exelixis, Inc. compostos para o tratamento de distúrbios dependentes de quinase
CA3088198A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR35044B (el) * 1966-05-10 1968-07-31 The Upjohn Company Μεθοδος παρασκευης οργανικων ενωσεων.
US4362739A (en) * 1981-05-04 1982-12-07 S.A. Omnichem Pyrrolo(2,3-d)carbazole derivatives, compositions and use
IL101851A (en) * 1991-06-13 1996-05-14 Janssen Pharmaceutica Nv 10-(4-piperidinyl- and piperidinylidene)-imidazo [1,2-a] (pyrrolo thieno or furano) [2,3] azepine derivatives their preparation and pharmaceutical compositions containing them and certain novel intermediates therefor
JPH09221475A (ja) * 1996-02-13 1997-08-26 Yamanouchi Pharmaceut Co Ltd 新規なオキシム誘導体
CA2297988A1 (en) * 1997-08-04 1999-02-11 Amgen Inc. Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
SG121852A1 (en) 1999-06-18 2006-05-26 Cv Therapeutics Inc Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
MY122278A (en) 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
JP5420908B2 (ja) * 2005-12-15 2014-02-19 エグゼリクシス， インコーポレイテッド 医薬的薬剤としてのアゼピノインドール誘導体

Also Published As

Publication number Publication date
WO2005009387A2 (en) 2005-02-03
EP1648408A4 (en) 2006-11-29
NO20060871L (no) 2006-04-24
US8466143B2 (en) 2013-06-18
CR8258A (es) 2006-08-30
CA2532798C (en) 2013-02-19
ECSP066392A (enExample) 2007-01-26
US20070015746A1 (en) 2007-01-18
CA2532798A1 (en) 2005-02-03
JP2006528637A (ja) 2006-12-21
JP4679517B2 (ja) 2011-04-27
KR20060052867A (ko) 2006-05-19
WO2005009387A3 (en) 2006-03-02
RU2006105646A (ru) 2007-09-10
EP1648408A1 (en) 2006-04-26
IL173287A0 (en) 2006-06-11
CN1852748A (zh) 2006-10-25
AU2004259009A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
BRPI0412262A (pt) derivados de azepina como agentes farmacêuticos
BRPI0417260A (pt) derivados de azepinoindol como agentes farmacêuticos
BRPI0513677B8 (pt) derivados de pirrol como agentes farmacêuticos
ECSP045139A (es) DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTICA DE MGluR5
BRPI0417820A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóide
BR0210028A (pt) Agentes antibacterianos
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
CY1118206T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει καλσιποτριολη και βηταμεθαζονη
UY26130A1 (es) Compuestos para tratar la obesidad
BR0313676A (pt) Derivados de pirimidina e uso destes como moduladores cb2
BR0112030A (pt) Novos compostos que possuem atividade antibacteriana, antifúngica ou antitumor
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BRPI0417771A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóides
NO20042964L (no) Spiroazasykliske forbindelser som monoaminreseptormodulatorer
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
DE60001974D1 (de) Derivate von flavonen, xanthonen und kumarinen
BR0314353A (pt) Compostos, composições farmacêuticas, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos, e, método para tratar um paciente que sofre de um distúrbio
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
BRPI0516883A (pt) compostos e métodos para modulação da atividade de trombopoietina
BRPI0514269A (pt) compostos heterocìclicos como agentes farmacêuticos
BR0113590A (pt) 7-oxo-piridopirimidinas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/55 (2006.01), A61P 9/00 (2006.01), C07D 22